[1111] PAX8 Immunohistochemical (IHC) Expression in Endocervical Glandular Lesions
Richard Danialan, Margaret Assaad, Richard W Cartun, Srinivas Mandavilli. Hartford Hospital/Clinical Laboratory Partners, Hartford, CT
Background: Glandular lesions of the endocervix can be diagnostically challenging and occasionally the differential diagnosis includes both endocervical (ECA) and endometrial adenocarcinomas (EmCA). PAX8 expression has been recently described in the normal endocervix, but there is limited literature evaluating its expression in benign and malignant endocervical lesions, particularly in the context of currently utilized IHC markers such as p16, Ki-67 and CEA. We wanted to evaluate the potential utility of PAX8 to this IHC panel.
Design: We searched our pathology files for benign cervical lesions including: microglandular hyperplasia (MGH), endocervical laminar hyperplasia (ELH), tuboendometrioid metaplasia (TEM), cervical endometriosis (CEM), and tunnel clusters (TC). Premalignant and malignant cohort included: endocervical adenocarcinoma in situ (EC AIS), invasive endocervical adenocarcinoma (ECA), and mucinous/ MGH variants of endometrial adenocarcinoma (EmCA). An IHC panel of CEA, Ki-67, p16 and PAX8 was performed on all cases. Immunoreactivity was scored on degree of positivity (S0 – no staining, S1- up to 10% cells staining, S2- between 10-50% cells staining, S3- >50% cells staining) and intensity (I1-mild, I2-moderate, I3-strong).
Results:
| Diagnosis/# of cases | CEA | Ki-67 | p16 | PAX8 |
| TC (5) | S0/I0 | S0/I0 | S1/I2 | S3/I2 |
| CEM (4) | S0/I0 | S1/I2 | S1/I3 | S3/I3 |
| ELH (2) | S0/I0 | S1/I1 | S1/I1 | S3/I2 |
| MGH (4) | S0/I0 | S0/I0 | S1/I2 | S2/I2 |
| TEM (2) | S0/I0 | S0/I0 | S1/I3 | S3/I2 |
| Diagnosis/# of cases | CEA | Ki-67 | p16 | PAX8 |
| ECA (3) | S2/I3 | S3/I2 | S3/I2 | S1/I1 |
| EC AIS (4) | S2/I2 | S2/I2-3 | S3/I2 | S2/I1 |
| EmCA (5) | S0/I1 | S2/I2-3 | S3/I3 | S3/I1-2 (4)* |